Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy

被引:144
作者
Lerner, SE
Blute, ML
Bergstralh, EJ
Bostwick, DG
Eickholt, JT
Zincke, H
机构
[1] MAYO CLIN & MAYO FDN,DEPT UROL,ROCHESTER,MN 55905
[2] MAYO CLIN & MAYO FDN,DEPT BIOSTAT,ROCHESTER,MN 55905
[3] MAYO CLIN & MAYO FDN,DEPT PATHOL,ROCHESTER,MN 55905
关键词
prostatectomy; prostatic neoplasms; risk factors;
D O I
10.1016/S0022-5347(01)65967-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Up to 26% of patients with pathologically organ confined prostate cancer will experience clinical progression after radical prostatectomy. We attempted to identify patients at greatest risk for future clinical failure despite a favorable pathological outcome. Materials and Methods: The study group included 904 patients treated with bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for disease confined to the prostate gland. Preoperative serum prostate specific antigen (PSA), clinical stage, pathological grade and stage, and deoxyribonucleic acid (DNA) ploidy were evaluated by multivariate analysis to determine relative value in predicting treatment failure. A prognostic scoring system was created using the regression coefficients from the Cox multivariate model to classify patients further according to risk of progression. Results: Preoperative PSA concentration, clinical stage, grade and DNA ploidy were significant univariate predictors of progression (p < 0.0001), whereas pathological stage was not (p = 0.2). Multivariate analysis identified pathological grade (p < 0.0001), preoperative serum PSA concentration (p = 0.0006) and DNA ploidy (p = 0.0089) as independent predictors of progression. The prognostic scoring system separated the patients into 5 distinct groups. Patients with the lowest score had a 92% progression-free survival rate at 5 years, compared to only 39% of those with the highest scores. Conclusions: Patients believed to be at higher risk for cancer progression despite having organ confined disease might be targeted for adjuvant therapy and closer surveillance, while those at low risk may be followed less often.
引用
收藏
页码:137 / 143
页数:7
相关论文
共 34 条
[1]  
[Anonymous], UROLOGIC PATHOLOGY
[2]   BILATERAL PELVIC LYMPHADENECTOMY AND RADICAL RETROPUBIC PROSTATECTOMY FOR ADENOCARCINOMA CONFINED TO THE PROSTATE [J].
BENSON, RC ;
TOMERA, KM ;
ZINCKE, H ;
FLEMING, TR ;
UTZ, DC .
JOURNAL OF UROLOGY, 1984, 131 (06) :1103-1106
[3]   COMBINING PROSTATE-SPECIFIC ANTIGEN WITH CANCER AND GLAND VOLUME TO PREDICT MORE RELIABLY PATHOLOGICAL STAGE - THE INFLUENCE OF PROSTATE-SPECIFIC ANTIGEN CANCER DENSITY [J].
BLACKWELL, KL ;
BOSTWICK, DG ;
MYERS, RP ;
ZINCKE, H ;
OESTERLING, JE .
JOURNAL OF UROLOGY, 1994, 151 (06) :1565-1570
[4]   PATTERN OF FAILURE AFTER RADICAL RETROPUBIC PROSTATECTOMY FOR CLINICALLY AND PATHOLOGICALLY LOCALIZED ADENOCARCINOMA OF THE PROSTATE - INFLUENCE OF TUMOR DEOXYRIBONUCLEIC-ACID PLOIDY [J].
BLUTE, ML ;
NATIV, O ;
ZINCKE, H ;
FARROW, GM ;
THERNEAU, T ;
LIEBER, MM .
JOURNAL OF UROLOGY, 1989, 142 (05) :1262-1265
[5]   DEOXYRIBONUCLEIC-ACID PLOIDY ANALYSIS AS A PREDICTOR OF RECURRENCE FOLLOWING RADICAL PROSTATECTOMY FOR STAGE T2 DISEASE [J].
CARMICHAEL, MJ ;
VELTRI, RW ;
PARTIN, AW ;
MILLER, MC ;
WALSH, PC ;
EPSTEIN, JI .
JOURNAL OF UROLOGY, 1995, 153 (03) :1015-1019
[6]   5-YEAR TUMOR RECURRENCE RATES AFTER ANATOMICAL RADICAL RETROPUBIC PROSTATECTOMY FOR PROSTATE-CANCER [J].
CATALONA, WJ ;
SMITH, DS .
JOURNAL OF UROLOGY, 1994, 152 (05) :1837-1842
[7]   RADICAL PROSTATECTOMY FOR PATHOLOGICAL STAGE-C PROSTATE-CANCER - INFLUENCE OF PATHOLOGICAL VARIABLES AND ADJUVANT TREATMENT ON DISEASE OUTCOME [J].
CHENG, WS ;
FRYDENBERG, M ;
BERGSTRALH, EJ ;
LARSONKELLER, JJ ;
ZINCKE, H .
UROLOGY, 1993, 42 (03) :283-291
[8]  
COX DR, 1972, J R STAT SOC B, V34, P187
[9]  
CULP OS, 1968, J UROLOGY, V98, P618
[10]  
EPSTEIN JI, 1993, CANCER-AM CANCER SOC, V71, P3582, DOI 10.1002/1097-0142(19930601)71:11<3582::AID-CNCR2820711120>3.0.CO